Cost of hospitalization for and risk factors associated with vancomycin-resistant Enterococcus faecium infection and colonization

被引:36
作者
Webb, M
Riley, LW
Roberts, RB
机构
[1] New York Hosp, Cornell Med Ctr, New York, NY 10021 USA
[2] Univ Calif Berkeley, Sch Publ Hlth, Div Infect Dis, Berkeley, CA 94720 USA
关键词
D O I
10.1086/321891
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The increase in costs of hospitalization for patients with drug-resistant infection may be associated with drug resistance itself or with the severity of the underlying illness that predisposes patients to acquire the drug-resistant infection. To address this issue, risk factors and cost of hospitalization were compared for patients infected or colonized with vancomycin-susceptible Enterococcus faecium (VSEF) or vancomycin-resistant E. faecium (VREF) in a large tertiary-care hospital in New York City. From January 1995 through December 1996, 157 patients with VSEF and 262 patients with VREF were identified. CMI (case-mix index) was assigned to each patient as a measure of severity of illness, with a CMI of 1 considered to represent illness of average severity. For all patients who were assigned a CMI of <3, the cost per day of hospitalization for patients with VREF was significantly greater than that for patients with VSEF. However, for patients with a CMI of >3, there was no difference between cost of hospitalization for patients with VREF and that for patients with VSEF. These observations indicate that, although vancomycin resistance is associated with an increased cost of hospitalization for less severely ill patients with VREF, patients with severe underlying illness, regardless of vancomycin resistance, incur similar hospitalization costs.
引用
收藏
页码:445 / 452
页数:8
相关论文
共 22 条
[1]  
ANDERSON GF, 1989, PROVIDING HOSP SERVI, P64
[2]   The incidence of and clinical variables associated with vancomycin-resistant enterococcal colonization in mechanically ventilated patients [J].
Bhorade, SM ;
Christenson, J ;
Pohlman, AS ;
Arnow, PM ;
Hall, JB .
CHEST, 1999, 115 (04) :1085-1091
[3]  
*CDCP, 1997, MMWR-MORBID MORTAL W, V46, P3
[4]   CLONAL SPREAD OF VANCOMYCIN-RESISTANT ENTEROCOCCUS-FAECIUM BETWEEN PATIENTS IN 3 HOSPITALS IN 2 STATES [J].
CHOW, JW ;
KURITZA, A ;
SHLAES, DM ;
GREEN, M ;
SAHM, DF ;
ZERVOS, MJ .
JOURNAL OF CLINICAL MICROBIOLOGY, 1993, 31 (06) :1609-1611
[5]   Prevalence and molecular epidemiology of glycopeptide-resistant enterococci in Belgian renal dialysis units [J].
Descheemaeker, P ;
Ieven, M ;
Chapelle, S ;
Lammens, C ;
Hauchecorne, M ;
Wijdooghe, M ;
Vandamme, P ;
Goossens, H .
JOURNAL OF INFECTIOUS DISEASES, 2000, 181 (01) :235-241
[6]   CDC DEFINITIONS FOR NOSOCOMIAL INFECTIONS, 1988 [J].
GARNER, JS ;
JARVIS, WR ;
EMORI, TG ;
HORAN, TC ;
HUGHES, JM .
AMERICAN JOURNAL OF INFECTION CONTROL, 1988, 16 (03) :128-140
[7]  
GOSS TF, 1998, 38 INT C ANT AG CHEM, P609
[8]   NOSOCOMIAL OUTBREAK DUE TO ENTEROCOCCUS-FAECIUM HIGHLY RESISTANT TO VANCOMYCIN, PENICILLIN, AND GENTAMICIN [J].
HANDWERGER, S ;
RAUCHER, B ;
ALTARAC, D ;
MONKA, J ;
MARCHIONE, S ;
SINGH, KV ;
MURRAY, BE ;
WOLFF, J ;
WALTERS, B .
CLINICAL INFECTIOUS DISEASES, 1993, 16 (06) :750-755
[9]   Insights into the epidemiology and control of infection with vancomycin-resistant enterococci [J].
Hayden, MK .
CLINICAL INFECTIOUS DISEASES, 2000, 31 (04) :1058-1065
[10]  
HOLMBERG SD, 1987, REV INFECT DIS, V9, P1065